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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not, “Is 
povidone-iodine safe and effective in the treatment of children and adults with viral 
conjunctivitis?” 
 
STUDY DESIGN: Review of three English language primary studies, published between 2002 
and 2015. 
 
DATA SOURCES: Two randomized controlled trials (RCTs) and one non-randomized, 
prospective, interventional pilot study were found using PubMed and the Cochrane database.   
 
OUTCOMES MEASURED: Each study evaluated the efficacy of povidone-iodine for the 
treatment of viral conjunctivitis measured by days until cured as determined by patient rating of 
symptom strength and ophthalmological grading of ocular signs.  Drug tolerability was defined 
as the proportion of participants sustaining povidone-iodine application until 7 days or recovery. 
 
RESULTS: Tunay, Ozdemir & Petricili (2015) found that a one-time irrigation with povidone-
iodine 2.5% and Netilmisin drops resulted in a significant reduction in symptom severity 
(p<0.05) and decreased time to recovery (p=0.001) as compared to instillation of Netilmisin 
alone.  Isenberg et al. (2002) found no significant difference (p =.133-.824) in the overall number 
of days until cured or proportion cured at week 1 between subjects receiving neomycin-
polymyxin-B-gramicidin and povidone-iodine 1.25% ophthalmic solutions 4 times daily.  
Trinavarat and Atchaneeyasakul (2012) found the recovery rate within a week of treatment with 
povidone-iodine 2% 4 times daily to be 77% (95%CI=65.1%-85.8%).  No severe adverse effects 
were found to be associated with povidone-iodine treatment in any of the three studies. 
  
CONCLUSION: Results of all 3 studies demonstrated that povidone-iodine is safe in the 
treatment of adenoviral conjunctivitis in infants, children, and adults.  Results also indicated that 
povidone-iodine may be an effective treatment for viral conjunctivitis by reducing the symptom 
severity and illness duration.  Further comparative studies are needed in order to prove the 
efficacy of povidone-iodine in viral conjunctivitis treatment. 
 
KEY WORDS: Povidone-iodine, Betadine, Conjunctivitis, Adenoviral conjunctivitis 
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INTRODUCTION 
 
 Acute viral conjunctivitis is a highly infectious, self-limited ocular disease spread via 
respiratory droplets, ocular secretions, and hand-to-eye contact.   It is most commonly caused by 
adenovirus.1 The condition typically presents with unilateral or bilateral corneal injection, watery 
discharge, foreign body sensation, ocular irritation, and crusted eyelids.  Signs of adenoviral 
conjunctivitis may include preauricular lymphadenopathy, chemosis, small conjunctival 
hemorrhages, and a follicular conjunctival reaction.1,2 
Viral conjunctivitis is extremely common, however, accurate epidemiological statistics 
for the isolated condition are unavailable.3  Laboratory isolation, via polymerase chain reaction 
assay (PCR) as a diagnostic tool is rarely utilized due to financial cost and time.4-6  Although 
time-sparing, user-friendly, with high sensitivity and specificity, rapid antigen immunoassay is 
also infrequently used in the clinical setting.7,8  Consequently, viral conjunctivitis is typically 
diagnosed clinically, and can be difficult to distinguish from bacterial conjunctivitis on clinical 
grounds alone.  As a result, healthcare providers usually treat all presenting cases of 
conjunctivitis empirically.3   
Research indicates that 6 million people annually in the United States suffer from 
conjunctivitis, with viral conjunctivitis being the most common cause of all infectious 
conjunctivitis cases.9  In addition, it is estimated that at least 1% of all primary healthcare visits 
in the U.S. are due to cases of conjunctivitis.10  Although viral conjunctivitis is a considerable 
economic burden, an accurate estimate of its specific healthcare costs has not yet been 
determined.11  An outbreak affecting 41 individuals in a U.S. hospital was found to cost the 
hospital $29, 527 ($1,085 in medical costs, $8,210 for investigatory measures, $3,084 for 
preventative measures, and $17,184 in productivity loss).1
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Although viral conjunctivitis is usually self-limited with resolution in 1-4 weeks, 
reasonable cause for concern exists due to its high rate of infectivity and possible complications.  
Keratitis is a severe complication which can manifest as epidemic keratoconjunctivitis (EKC).  
EKC occurs worldwide in the general population, hospitals, neonatal ICUs, and nursing homes.13  
The condition remains infectious for 10-14 days after onset of symptoms.14  Diagnosed patients 
are advised to limit personal contact, resulting in several missed work or school days.  In severe 
cases, pseudomembrane formation and multifocal subepitheliel infiltrates can lead to the 
development of subepitheliel fibrosis, symblepharon, and permanent vision loss.15,16  
Currently, no specific curative treatment exists for viral conjunctivitis and standard 
therapy is thus supportive.  Topical antibiotics such as ofloxacin and neomycin are used in order 
to treat or prevent bacterial infection.17 For symptomatic relief, cool compresses, artificial tears, 
topical antihistamines, and vasoconstrictors are commonly employed.18 Topical steroids such as 
prednisolone acetate 1% are typically reserved for severe cases as they can result in prolongation 
of the disease course.19,20  
Povidone-iodine (Betadine; PVP-I) is an antimicrobial antiseptic agent that is highly 
effective against multiple microorganisms, including adenovirus.  It has been successfully 
utilized pre and post operatively in ophthalmological surgery, and in ophthalmia neonatorum 
prophylaxis.21-24  PVP-I may serve as a cost-effective alternative in shortening the duration and 
intensity of symptoms in viral conjunctivitis in both developing countries and the U.S.  PVP-I is 
also an attractive alternative due to increasing rates of antibiotic resistance in the U.S.25 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not povidone-
iodine is safe and effective in the treatment of children and adults with viral conjunctivitis.
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METHODS 
 Two double blind, randomized controlled trials, and one non-randomized, prospective, 
interventional pilot study were included in this systemic review.  The populations of interest for 
this review included individuals of any age, gender, or race suffering from viral conjunctivitis.  
The outcomes of interest used in selection of studies included efficacy and tolerability of 
povidone-iodine.  Studies were selected if they compared interventional treatment with PVP-I to 
a commonly utilized ocular antibiotic or placebo control.  Uncontrolled studies that assessed the 
efficacy and tolerability of PVP-I with a course of treatment were also considered for review.  
All studies selected were published in the English language in peer-reviewed journals.  
The author utilized the Cochrane Systemic Reviews and PubMed databases for articles published 
after the year 2000 with the keywords, “Povidone-iodine, “Betadine,” “viral conjunctivitis,” and 
“adenoviral conjunctivitis.”  Studies were included if they were POEM based and if they 
evaluated the safety and efficacy of povidone-iodine in patients diagnosed with viral 
conjunctivitis.  Exclusion criteria included studies solely investigating subjects with diagnosed 
bacterial conjunctivitis.  After extensive review of the literature, 2 randomized controlled trials 
and one uncontrolled, interventional pilot study, all published between the years 2002 and 2014, 
were selected for the current review.  Refer to Table 1 for individual demographics of each 
study.  Statistics reported in the 3 studies included means, standard deviations, percent change 
from baseline, confidence intervals, and p-values. 
Table 1: Demographics and characteristics of included studies 
Study Type # 
Pts 
Age Inclusion 
Criteria 
Exclusion 
Criteria 
W/
D 
Interventio
n 
Tunay, 
201526 
RCT 35 1-
4mos 
Infants with 
ophtho exam 
demonstratin
g + ocular 
symptoms or 
a + Rapid 
Bacterial growth 
in conjunctival 
swab culture; use 
of ophthalmic 
drops in past 2 
wks. 
0 Single dose  
PVP-I 2.5% 
solution 
followed by 
artificial 
tears and 
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Pathogen 
Screening-
Adeno 
Detector Test 
result 
Netilmisin 
0.3% VS 
artificial 
tears and 
Netilmisin  
Trinavarat
, 201214 
Interventional
, uncontrolled 
pilot study 
61 10-
84yrs 
Pts with 
clinical 
diagnosis of 
EKC 
<6yrs; 
pregnant/lactating
; PVP-I allergy; 
prior ocular 
surgery; contact 
lens use; chronic 
eye disease; 
current use of eye 
medication 
13 PVP-I 2% 
solution 
applied to 
affected eye 
4x a day for 
1 week or 
until 
recovery 
Isenberg, 
200217 
RCT 221 7mos
-
21yrs 
1mo-21yrs 
with history 
of untreated 
red inflamed 
eye with 
discharge ≤14 
days with 2+  
findings of 
viral 
conjunctivitis 
on exam  
+ bacterial 
cultures, no eye 
discharge; ocular 
antibiotic use ≤14 
days, pruritic eyes 
with giant papillae 
of tarsal 
conjunctivae; 
allergy to PVP-I, 
neomycin, 
polymyxin, or 
bacitracin; 
perforated 
sclera/cornea; 
hypopyon 
84* PVP-I 
1.25% 
solution in 
affected eye 
4 times daily 
VS 
neomycin-
polymyxin 
B-
gramicidin 
in affected 
eye 4 times 
daily 
*In Isenberg et al., 43 pts in the PVP-I group dropped out and 41 in the Abx group dropped out.  
This study investigated both bacterial and viral conjunctivitis and did not specify drop-out rates based on 
infectious origin. 
  
OUTCOMES MEASURED 
Tunay et al.26 randomly divided 35 infants with EKC into two groups during an outbreak 
in a neonatal ICU.  Diagnosis was based upon ophthalmologic exam and negative bacterial 
cultures. The affected eyes of Group 1 (n=15) were irrigated with a single dose of PVP-I 2.5% 
solution, followed by artificial tears (sodium hyaluronate 0.15%, 6X1) and antibiotic drops 
(Netilmisin 0.3%, 4X1).  Group 2 infants (n=20) were treated with artificial tears and Netilmisin 
alone.  The eyes were anesthetized prior to treatment.  The outcome of PVP-I efficacy was 
measured by days until recovery and strength of symptoms.  Patients were examined twice 
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weekly until recovery, which was defined as the absence of ocular findings on ophthalmological 
exam.  Findings of lid edema, conjunctival chemosis, and fragility of conjunctival vasculature 
were scored on a 0 to 3 scale (0=none, 1=mild, 2=moderate, 3=severe).  Presence or absence of 
pseudomembrane formation was also recorded. 
In an interventional, uncontrolled pilot study, Trinavarat and Atchaneeyasakul14 treated 
61 patients during 2 episodes of EKC (𝑥 age=41.7yrs) with PVP-I 2% in each affected eye 4 
times daily for one week.  Diagnosis was based upon ophthalmological exam at an outpatient 
ophthalmic clinic.  The main outcomes were recovery rate within one week of treatment, and 
drug tolerability.  Drug tolerability was defined as the proportion of subjects sustaining treatment 
until recovery or after 7 days of treatment.  Participants graded symptoms of lid swelling, 
injection, irritation, foreign body sensation, tearing, light sensitivity, and general discomfort as 
none, mild, moderate, or severe at baseline and at day 7.  Investigator measures included ratings 
at baseline and day 7 of blepharedema, conjunctival congestion/ chemosis, subconjunctival 
hemorrhage, follicular reactions, eye discharge, corneal involvement, anterior chamber reaction, 
and preauricular lymphadenopathy. Recovery was defined as absence of ocular discomfort. 
In a double-blind RCT, Isenberg et al.17 treated 221 individuals (𝑥=6.6yrs) with viral 
conjunctivitis in an outpatient ophthalmology clinic with either PVP-I 1.25% or neomycin-
polymyxin-B-gramicidin ophthalmic solution one drop 4 times daily in each affected eye 
(administered by the patient). Diagnosis was based upon clinical exam findings and negative 
bacterial cultures.  Efficacy was measured as days until cured and proportion cured after 1 week 
of treatment.  Patients graded the degree of eye inflammation as none, mild, moderate, or severe 
utilizing colored illustrations of eyes on a daily basis while also recording any adverse effects.  
Weekly ophthalmological grading was performed in categories of conjunctival redness, eyelid 
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swelling, and discharge, rated on a 0 (none) to 5 (severe) scale, with a total score of 0 being 
indicative of a cured infection.
RESULTS 
Two studies compared PVP-I solution with antibiotic solution 4 times daily and one with 
single-dose PVP-I followed by Netilmisin drops in the treatment of viral conjunctivitis.  A third 
uncontrolled study investigated tolerability and recovery rate of PVP-I 4 times daily.  One study 
involved infants diagnosed with EKC in a neonatal ICU as participants, while the other two 
included both children and adults in an outpatient setting. 
Tunay et al.26 treated 15 infants with a single dose of PVP-I 2.5% followed by artificial 
tears and antibiotic drops (Group 1), and 20 infants with artificial tears and antibiotic drops 
(Group 2). Median clinical scores of ocular findings (Table 2) were found to be significantly 
lower in Group 1 than in Group 2 (p <0.05) at day 7 of treatment. 
Table 2: Ocular findings and recovery times between Group 1 and Group 2 (Tunay et al.) 
Ocular Findings Group 1 (n=15) 
(min-max) 
Group 2 (n=20) 
(min-max) 
p*  Value 
Lid edema 1 (0-2) 2 (1-3) 0.0001 
Conjunctival chemosis 1 (1-2) 2 (2-3) 0.0001 
Fragility of conjunctival vasculature 1 (0-2) 3 (2-3) 0.0001 
Recovery time (day) 7 (6-9) 12 (9-18) 0.0001 
Pseudomembrane formation (%) % 6 (n=1) % 45 (n=9) 0.021** 
Min, minimum; max, maximum 
*Mann-Whitney U test 
**Fisher’s exact test 
 
Median recovery rate was also significantly lower in Group 1 (7d) than in Group 2 (12d) 
(p=0.001).26 Total recovery in 7 days occurred in 60% of infants in Group 1 (EER), and 5% of 
infants in Group 2 (CER). The relative benefit increase (RBI) and absolute benefit increase 
        Mazzuca, Povidone-iodine and Conjunctivitis             7
(ABI) were calculated to be 11% and 55%, respectively.  The number needed to treat (NNT) in 
this study was calculated to be 2 (Table 3).  A NNT of 2 indicates that for one patient to benefit 
from treatment with PVP-I, 2 patients must be treated. 
Table 3: Efficacy of PVP-I 2.5% on recovery time: NNT (Tunay et al.) 
Proportion of patients 
with total recovery in 
7 days on antibiotic 
drops alone (CER) 
Proportion of patients 
with total recovery in 
7 days on PVP-I and 
antibiotic drops (EER) 
Relative 
benefit 
increase 
(RBI) 
Absolute 
benefit 
increase 
(ABI) 
Number needed 
to treat (NNT) 
.05 .60 11 .55 2 
 
Trinavarat et al.14 found the recovery rate within 7 days of treatment with PVP-I 2% to be 
77% (95% CI=65.1%-85.8%) as demonstrated by the absence of general ocular discomfort in 47 
participants (Table 4).  Significant reduction in severity of the majority of eye findings and 
symptoms occurred between comparison at baseline and at day 7 (p=0.000), with complete 
disappearance of preauricular lymphadenopathy.  At baseline, superficial punctate keratitis 
occurred in 5 (8.2%) eyes, while subepitheliel infiltration occurred in 1 (1.6%) eye.  At day 7, 
superficial punctate keratitis was found in 7 (11.5%) eyes, and subepitheliel infiltration in 2 
(3.3%) eyes.  Thus, PVP-I 2% could not completely prevent corneal involvement. 
Table 4: Recovery rate within 7 days of PVP-I 2% treatment (Trinavarat et al.) 
Pts with ocular 
discomfort, 
Baseline 
Pts with ocular 
discomfort, Day 
7 
P-value Recovery rate 
within 7 days 
95% CI 
N=61(100%) N=14 (22.9%) 0.000 77.0% 65.1%-85.8% 
 
Isenberg et al.17 treated a total of 459 children diagnosed with either bacterial, viral 
(n=221), or chlamydial conjunctivitis with PVP-I 1.25% or neomycin-polymyxin-B-gramicidin 
ophthalmic solution. Eighty-four participants dropped out of the study without returning to the 
treatment facility for follow-up. The authors do not specify the drop-out rate in terms of 
infectious etiology, but rather by treatment group, with 43 drop-outs in the PVP-I group and 41 
in the antibiotic group (p=.74).  Due to the similarity of drop-out rates across treatment groups, 
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these cases were not considered in the final analysis as statistical outcomes would not have been 
altered even if they were included as treatment failures.  
The number of days until cured as rated by the ophthalmologist was 8.8 (SD=2.8) for the 
PVP-I group, and 9.0 (SD=3.0) for the antibiotic group17.  As rated by the patient, days until cure 
was 5.8 (SD=3.0) for the PVP-I group, and 5.7 (SD=2.8) for the antibiotic group.  The authors 
found no significant difference in days until recovery between the PVP-I and the antibiotic 
groups (p=.150).   
The proportion cured by day 7 was also not found to be significant between the 2 groups 
(p=.133).17 As rated by the ophthalmologist, the percent cured was 56.3% in the PVP-I group 
(EER), and 52.0% in the antibiotic group (CER).  The RBI was calculated to be 8.27%, while the 
ABI was 4.3%.  The numbers needed to treat (NNT) was determined to be 24 (Table 5).   
Table 5: Efficacy of PVP-I 1.25% on ophthal rated recovery time: NNT (Isenberg et al.) 
Proportion of patients 
with total recovery in 7 
days, antibiotic drops 
alone (CER) 
Proportion of patients 
with total recovery in 
7 days on PPV-I 
alone (EER) 
Relative 
benefit 
increase 
(RBI) 
Absolute 
benefit 
increase 
(ABI) 
Number 
needed to 
treat (NNT) 
.52 .563 .0827 .043 24 
 
The percent cured by day 7 as rated by the patient was 77.2% in the PVP-I group (EER), 
and 78.6% in the antibiotic group (CER).  The resulting RBI was calculated to be 2.69%, while 
the ABI was 1.4%.  The NNT was determined to be 72 (Table 6). 
Table 6: Efficacy of PVP-I 1.25% on patient rated recovery time: NNT (Isenberg et al.) 
Proportion of patients 
with total recovery in 7 
days, antibiotic drops 
alone (CER) 
Proportion of patients 
with total recovery in 
7 days on PPV-I 
alone (EER) 
Relative 
benefit 
increase 
(RBI) 
Absolute 
benefit 
increase 
(ABI) 
Number 
needed to 
treat (NNT) 
.786 .772 .0269 .014 72 
 
Trinavarat et al.14 assessed drug tolerability, defined as the proportion of participants able 
to sustain PVP-I 2% for 7 days or until complete recovery.  The tolerability rate was calculated 
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to be 78.7% (95% CI=66.9%-87.1%).  Thirteen participants dropped out of the study prior to 
recovery or 7 days of treatment due to reported stinging in the treated eye (Table 7).  Neither 
Tunay et al.26, nor Isenberg et al.17 found any significant adverse or toxic effects of PVP-I 2.5% 
and PVP-I 1.25% treatment, respectively.   
Table 7: Tolerability of PVP-I (Trinavarat et al.) 
Study Adverse effect # of participants 
with stinging 
Tolerability rate 95% CI 
Trinavarat et 
al.14 
Stinging 13 (21.3%) 78.7% 66.9%-87.1% 
 
DISCUSSION 
 Although viral conjunctivitis is typically a self-limited condition, its high rate of 
infectivity, epidemic outbreaks, social and economic burden, and rare but severe complications 
warrant investigation of a safe and effective treatment.  Antibiotics may help to prevent rare 
opportunistic bacterial infections, but they are unsuccessful at reducing rate of recovery or 
symptom strength,17 while antiviral agents actually prolong the course of infection.19,20 
Povidone-iodine is a commonly utilized antiseptic agent that is both cost-effective and 
readily available in the U.S. and abroad.  It has been successfully utilized in the prophylaxis of 
neonatal conjunctivitis, as well as pre-surgical and post-cataract surgery endopthalmititis.21-24 
PVP-I is pregnancy Category C due to its poorly understood effects on the neonatal thyroid 
gland.27 The only absolute contraindication is iodine hypersensitivity, which is extremely rare.  
Severe ocular or systemic side effects have not been reported in the literature.  Although local 
side effects such as a stinging sensation (as reported in Trinavarat et al.14) may occur, this effect 
can be easily avoided by topical anesthesia, followed by irrigation and swabbing of the lids.14 
This side effect has not been found to result in any long-term sequelae.28  
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The most effective method of treatment delivery with PVP-I has yet to be determined.  
Each study in this review utilized different solution potencies and dosing regimens.  Regardless 
of the potency used, all studies found PVP-I to be safe and tolerable.  The Trinavarat et al.14 
study is limited by the absence of a comparison control group.  While Tunay et al.26 concluded 
that PVP-I 2.5% was significantly effective in reduction of symptom severity and recovery time, 
Isenberg et al.17 demonstrated PVP-I 1.25% to be as ineffective as antibiotic treatment.  The 
differing results could be due to several factors such a PVP-I potency, dosing regime, or patient 
age.   
In Trinavarat et al.14, reliability could have been improved with laboratory confirmation 
of a viral causative agent.  However, this methodology itself is a reflection of standard clinical 
procedure, with confirmatory diagnostics rarely indicated and often unavailable. Patient 
compliance in Trinavarat et al.14 and Isenberg et al.17 also could not be guaranteed, as PVP-I was 
self-administered by patients outside of the treatment facility.  
Determination of a “cured” case is subject to both ophthalmological and patient 
subjectivity.  Aside from the effects of personal clinical judgement, the diagnostic criteria itself 
varied across studies.  Lastly, this review itself is limited by the minimal number of RCT trials 
available in the literature, each with varying methodology. 
CONCLUSION 
 Based upon evaluation of these 3 studies, it can be concluded that povidone-iodine 
ophthalmic solution is safe in the treatment of viral conjunctivitis of infants, children, and adults.  
However, it remains inconclusive as to whether or not povidone-iodine is any more effective 
than antibiotics or symptomatic treatment alone.  Future studies conducted in a controlled 
environment comparing the efficacy of povidone-iodine solution versus symptomatic treatment 
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alone are warranted.  Additionally, the use of a quick diagnostic screening tool such as the RPS 
Adeno Detector in future studies will aid in strengthening the reliability and validity of research 
outcomes.
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